Lampalizumab

Lampalizumab (INN) is an antigen-binding fragment of a humanized monoclonal antibody that binds to complement factor D; it was developed as a potential treatment of geographic atrophy (atrophy of the retinal cells, retinal pigment epithelium, and choriocapillaris) secondary to age-related macular degeneration.[1][2]

Lampalizumab
Monoclonal antibody
TypeFab fragment
SourceHumanized (from mouse)
TargetCFD
Clinical data
Routes of
administration
Intravitreal
ATC code
  • none
Identifiers
CAS Number
IUPHAR/BPS
ChemSpider
  • none
KEGG
Chemical and physical data
FormulaC2068H3214N546O676S13
Molar mass46.96 kg/mol g·mol−1

One of the two Phase 3 clinical trials (Spectri) was interrupted on September 8, 2017 due to failure to meet primary end point.[3] The second Phase 3 clinical trial (Chroma) also failed to meet its primary end point.[4]

These two failures have called into question whether complement inhibition is a sound strategy for geographic atrophy.[5]

References


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.